Navigation Links
Ophthalmology Pioneer Dr. Jeffrey P. Gilbard Dies
Date:8/13/2009

WOBURN, Mass., Aug.13 /PRNewswire/ -- Dr. Jeffrey P. Gilbard, a pioneer in dry eye disease, died Wednesday, August 12, 2009 at Massachusetts General Hospital in Boston. Doctors say the cause of death was complications related to a bicycle accident. He was 55 years old.

Dr. Gilbard is best known for his pioneering research that led to treatments for dry eye disease, a condition that is caused by a chronic lack of moisture in the eye. He also is considered one of the first ophthalmologists and researchers to understand the correlation between nutrition and the health and wellness of the eye.

Dr. Gilbard founded Advanced Vision Research (AVR) in 1995 to market and distribute TheraTears, a revolutionary over-the-counter eye drop he created to treat dry eye. TheraTears quickly became one of the best selling eye lubricants on the market. His holistic approach to eye care included the use of nutritional supplements to improve the ocular surface and to treat and prevent retinal disease. This research resulted in additional products including TheraTears Nutrition, Macutrition and NutriDox.

With numerous patents and 11 products available in stores worldwide, the company has had record sales for 12 consecutive years. The AVR executive team led by Chief Operating Officer Leigh Reynolds will continue to run the company. Neil D. Donnenfeld, senior vice president of Global Sales and Marketing and Ruth Webb who serves as controller will continue to grow the business and offer new products into the marketplace.

"Our company is grieving the loss of its founder and our close friend, Dr. Jeffrey Gilbard," says Leigh Reynolds. "Over the past 12 years, I have worked closely with Jeff to build AVR. Jeff's vision for AVR to make products to prevent suffering due to dry eye and other eye diseases was very clear. We will continue his mission of improving people's quality of life. This is what Jeff would want us to do and there's no better tribute to him than to continue his work."

Neil Donnenfeld adds: "Jeff was blessed with extraordinary intellect and dedication. He combined the two and made a significant difference in the world. He had no greater satisfaction than to hear that one of AVR's products helped a dry-eye sufferer - and he heard that frequently. His legacy will live on through the relief that dry-eye sufferers receive when they use one of his products. We have lost a giant of a man."

In the summer of 1976, as a medical student, Dr. Gilbard met his first patient with dry-eye and decided something had to be done. What began as a summer research project turned into one of the most productive dry eye research programs in the world. In 1978 he received project grant funding from the National Eye Institute, and to this day he remains the youngest scientist in history to have received such funding. His research program had one goal - to develop an eye drop for dry eyes that really worked.

"Jeff Gilbard was an innovative, gifted ophthalmologist and researcher, who made several important contributions to our profession," said Dr. Edward Holland, director of Cornea Service at the Cincinnati Eye Institute. "He was the first person to understand the importance of tear film osmolarity and his development of hypotonic artificial tears containing bicarbonate and potassium is a landmark event in the treatment of dry eye disease. Dr. Gilbard was on the forefront of the treatment of ocular disease and nutritional supplements. Dr. Gilbard's legacy will be the scientific papers he authored, the revolutionary products he developed to help patients with ocular surface and retinal disease and most notably the people whose lives he'll continue to improve."

Born on February 19, 1954 and raised in Roslyn, New York he was the son of a self-educated New York business entrepreneur Harris Gilbard and Frances Gilbard. He attended Brown University, receiving his Bachelor of Arts degree, Magna Cum Laude in 1975. He received his medical degree in 1979 from the College of Physicians and Surgeons at Columbia University. He was an Intern in Internal Medicine at Stanford University Medical Center and served his Ophthalmology residency at Harvard Medical School in the Massachusetts Eye and Ear Infirmary. He remained at Harvard as a Heed Fellow in Cornea. He was a clinical assistant professor of Ophthalmology at Harvard Medical School and director of the Dry Eye and Ocular Surface Disease Clinic at the New England Eye Center in Boston.

Dr. Jeffrey Gilbard is survived by his beloved wife of 19 years, Liz and his three children, who he adored and nurtured. He also leaves behind his twin brother Dr. Steven M. Gilbard, his older brother Dr. Robert J. Gilbard. A memorial service will take place on Monday at 11:00 am at Temple Shir Tikva, 141 Boston Post Road, Wayland, Massachusetts.


'/>"/>
SOURCE Advanced Vision Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA
2. American Academy of Ophthalmology Honors PBS Master Carpenter Norm Abram for His Commitment to Eye Safety
3. Ophthalmology highlights Jan. 2009
4. Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA
5. Long-Term Results of VisionCares Implantable Telescope for End-Stage Macular Degeneration Published in the American Journal of Ophthalmology
6. Second Annual Eye Ball Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology
7. The Most Ordinary Things Can Cause the Most Extraordinary Eye Injuries, Says the Oklahoma Academy of Ophthalmology
8. September Ophthalmology research highlights
9. Highlights from the August 2008 issue of Ophthalmology
10. Mergent, Inc. Announces Changes to the HealthShares(TM) Ophthalmology Index
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... California (PRWEB) , ... May 30, 2016 , ... ... easy to use inside of FCPX," said Christina Austin - CEO of Pixel ... exclusively for use within Final Cut Pro X. Choose from abstract transitions to ...
(Date:5/29/2016)... , ... May 29, 2016 , ... Whole Health Supply ... their new KlipPro KP-240L clipper is available to the public. This is an unusual ... substantially wider than the average clipper. , Everything about this product is concentrated on ...
(Date:5/28/2016)... Hartford, CT (PRWEB) , ... May 28, 2016 , ... After a year and a ... report it was an extraordinary event. The Multiple Pathways of Recovery Conference was held ... from across the country and the United Kingdom came together to explore the many pathways ...
(Date:5/27/2016)... ... 27, 2016 , ... W.S. Badger Co. Inc ., the maker of ... recognized as one of the best small businesses for new dads by Fatherly, the ... small businesses providing progressive benefits to new parents on the organization’s 2016 Best ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response to meager public ... unaware of the plight of aphasia. In collaboration with the American Aphasia Association, ... , The link between stroke and aphasia is relatively unknown, but through collaboration ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient ... bei Brustkrebs   QIAGEN N.V. (NASDAQ: ... gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit ... Assays für die Onkologie eingegangen zu sein. Ein ...
Breaking Medicine Technology: